Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
Authors:
- Nasiri, Mohammad Javad
- Zangiabadian, Moein
- Arabpour, Erfan
- Amini, Sirus
- Khalili, Farima
- Centis, Rosella
- D'Ambrosio, Lia
- Denholm, Justin T.
- Schaaf, H. Simon
- van den Boom, Martin
- Kurhasani, Xhevat
- Dalcolmo, Margareth Pretti
- Al-Abri, Seif
- Chakaya, Jeremiah
- Alffenaar, Jan-Willem
- Akkerman, Onno
- Silva, Denise Rossato
- Muňoz-Torrico, Marcela
- Seaworth, Barbara
- Pontali, Emanuele
- Saderi, Laura
- Tiberi, Simon
- Zumla, Alimuddin
- Migliori, Giovanni Battista
- Sotgiu, Giovanni
Details:
International Journal of Infectious Diseases, Volume 124, 2022-11-30
Article Link: Click here
Introduction Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. Methods We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant. Results After reviewing 626 records, we identified 25 studies that met the inclusion criteria, 22 observational and 3 experimental, with 1276 and 411 patients, respectively. In observational studies the overall pooled treatment success rate of DLM-containing regimens was 80.9% (95% CI 72.6-87.2) with no evidence of publication bias (Begg's test; P >0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P <0.001, I2: 95.1%) with no evidence of publication bias (Begg's test; P >0.05). Conclusions In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.